News

Santé log2h
SBC Medical Appoints New Chief Marketing Officer to Enhance Marketing Infrastructure and Strengthen Brand Power
Comment from CEO Yoshiyuki Aikawa “We are delighted to welcome Mr. Shinya Inoue as our new CMO. He brings exceptional ...
Santé log2h
Breckenridge Distillery Unveils Limited-Edition Collectors Art Series Collaboration with Renowned Artist Miles Toland
Breckenridge Distillery is a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a leading global ...
Santé log2h
Bio Usawa Biotechnology and Bioeq AG Partner to Create Widespread Access to Vision-Saving Medicine Across Sub-Saharan Africa
Bioeq AG is a Swiss biopharmaceutical joint venture between Polpharma Biologics Group and Formycon AG. Bioeq develops and licenses biosimilars for global markets, combining innovation and quality to ...
Santé log2h
Unnatural Products Announces Multi-Target Collaboration with argenx to Develop Oral Macrocyclic Peptide Therapeutics
UNP’s platform combines AI-guided compound design, massively parallel synthesis, and direct-to-biology screening, enabling the rapid generation of drug-like macrocycles that bind challenging targets ...
Santé log2h
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, has exercised its option to license Abeona's ...
Santé log2h
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
Under the terms of the agreement, Sobi will acquire 90% of Apellis’ ex-U.S. royalties for Aspaveli for $275 million in cash. Apellis will also be eligible for up to $25 million in milestone payments ...
Santé log2h
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity ...
Santé log2h
Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025
About VYKAT XR VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to U.S. patients. VYKAT XR is indicated for the treatment of ...
Santé log2h
NewGen Subsidiary Secures Strategic UAE Land and Begins Exploration of Potential Real World Asset Tokenization Initiative
The tokenization initiative would be made in connection with a real estate project with a projected sales revenue exceeding US$400 million. BANGKOK, July 01, 2025 (GLOBE NEWSWIRE) ...
Santé log2h
EDAP Announces Transition from Foreign Private Issuer to U.S. Domestic Filer Status
Transition to U.S. reporting status to take effect on January 1, 2026 ...
Santé log2h
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study ...
Santé log2h
T-knife Therapeutics Appoints Christoph Broja to its Board of Directors
SAN FRANCISCO and BERLIN, July 01, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer ...